Literature DB >> 33512408

TLR9 expression in chronic lymphocytic leukemia identifies a promigratory subpopulation and novel therapeutic target.

Emma Kennedy1, Eve Coulter2,3, Emma Halliwell4, Nuria Profitos-Peleja5, Elisabeth Walsby6, Barnaby Clark7, Elizabeth H Phillips3,8, Thomas A Burley1, Simon Mitchell1, Stephen Devereux3, Christopher D Fegan6, Christopher I Jones9, Rosalynd Johnston10, Tim Chevassut1,10, Ralph Schulz11, Martina Seiffert11, Angelo Agathanggelou12, Ceri Oldreive12, Nicholas Davies12, Tatjana Stankovic12, Triantafillos Liloglou13, Chris Pepper1, Andrea G S Pepper1.   

Abstract

Chronic lymphocytic leukemia (CLL) remains incurable despite B-cell receptor-targeted inhibitors revolutionizing treatment. This suggests that other signaling molecules are involved in disease escape mechanisms and resistance. Toll-like receptor 9 (TLR9) is a promising candidate that is activated by unmethylated cytosine guanine dinucleotide-DNA. Here, we show that plasma from patients with CLL contains significantly more unmethylated DNA than plasma from healthy control subjects (P < .0001) and that cell-free DNA levels correlate with the prognostic markers CD38, β2-microglobulin, and lymphocyte doubling time. Furthermore, elevated cell-free DNA was associated with shorter time to first treatment (hazard ratio, 4.0; P = .003). We also show that TLR9 expression was associated with in vitro CLL cell migration (P < .001), and intracellular endosomal TLR9 strongly correlated with aberrant surface expression (sTLR9; r = 0.9). In addition, lymph node-derived CLL cells exhibited increased sTLR9 (P = .016), and RNA-sequencing of paired sTLR9hi and sTLR9lo CLL cells revealed differential transcription of genes involved in TLR signaling, adhesion, motility, and inflammation in sTLR9hi cells. Mechanistically, a TLR9 agonist, ODN2006, promoted CLL cell migration (P < .001) that was mediated by p65 NF-κB and STAT3 transcription factor activation. Importantly, autologous plasma induced the same effects, which were reversed by a TLR9 antagonist. Furthermore, high TLR9 expression promoted engraftment and rapid disease progression in a NOD/Shi-scid/IL-2Rγnull mouse xenograft model. Finally, we showed that dual targeting of TLR9 and Bruton's tyrosine kinase (BTK) was strongly synergistic (median combination index, 0.2 at half maximal effective dose), which highlights the distinct role for TLR9 signaling in CLL and the potential for combined targeting of TLR9 and BTK as a more effective treatment strategy in this incurable disease.
© 2021 by The American Society of Hematology.

Entities:  

Mesh:

Substances:

Year:  2021        PMID: 33512408      PMCID: PMC8176769          DOI: 10.1182/blood.2020005964

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  59 in total

1.  A role for Toll-like receptors in acquired immunity: up-regulation of TLR9 by BCR triggering in naive B cells and constitutive expression in memory B cells.

Authors:  Nadia L Bernasconi; Nobuyuki Onai; Antonio Lanzavecchia
Journal:  Blood       Date:  2003-01-30       Impact factor: 22.113

2.  CD38 increases CXCL12-mediated signals and homing of chronic lymphocytic leukemia cells.

Authors:  T Vaisitti; S Aydin; D Rossi; F Cottino; L Bergui; G D'Arena; L Bonello; A L Horenstein; P Brennan; C Pepper; G Gaidano; F Malavasi; S Deaglio
Journal:  Leukemia       Date:  2010-03-11       Impact factor: 11.528

3.  Distinct innate immunity pathways to activation and tolerance in subgroups of chronic lymphocytic leukemia with distinct immunoglobulin receptors.

Authors:  Stavroula Ntoufa; Anna Vardi; Nikos Papakonstantinou; Achilles Anagnostopoulos; Vassiliki Aleporou-Marinou; Chrysoula Belessi; Paolo Ghia; Federico Caligaris-Cappio; Marta Muzio; Kostas Stamatopoulos
Journal:  Mol Med       Date:  2012-12-06       Impact factor: 6.354

Review 4.  Revisiting STAT3 signalling in cancer: new and unexpected biological functions.

Authors:  Hua Yu; Heehyoung Lee; Andreas Herrmann; Ralf Buettner; Richard Jove
Journal:  Nat Rev Cancer       Date:  2014-11       Impact factor: 60.716

5.  The Akt signaling pathway determines the different proliferative capacity of chronic lymphocytic leukemia B-cells from patients with progressive and stable disease.

Authors:  P G Longo; L Laurenti; S Gobessi; A Petlickovski; M Pelosi; P Chiusolo; S Sica; G Leone; D G Efremov
Journal:  Leukemia       Date:  2006-10-05       Impact factor: 11.528

6.  Lack of TIR8/SIGIRR triggers progression of chronic lymphocytic leukemia in mouse models.

Authors:  Maria Teresa Sabrina Bertilaccio; Giorgia Simonetti; Antonis Dagklis; Martina Rocchi; Tania Veliz Rodriguez; Benedetta Apollonio; Alberto Mantovani; Maurilio Ponzoni; Paolo Ghia; Cecilia Garlanda; Federico Caligaris-Cappio; Marta Muzio
Journal:  Blood       Date:  2011-06-07       Impact factor: 22.113

7.  Treatment with Ibrutinib Inhibits BTK- and VLA-4-Dependent Adhesion of Chronic Lymphocytic Leukemia Cells In Vivo.

Authors:  Sarah E M Herman; Rashida Z Mustafa; Jade Jones; Deanna H Wong; Mohammed Farooqui; Adrian Wiestner
Journal:  Clin Cancer Res       Date:  2015-06-18       Impact factor: 12.531

8.  CD38 expression in chronic lymphocytic leukemia is regulated by the tumor microenvironment.

Authors:  Piers E M Patten; Andrea G S Buggins; Julie Richards; Andrew Wotherspoon; Jon Salisbury; Ghulam J Mufti; Terry J Hamblin; Stephen Devereux
Journal:  Blood       Date:  2008-03-07       Impact factor: 22.113

9.  Regulation of migration and invasion by Toll-like receptor-9 signaling network in prostate cancer.

Authors:  Yun Luo; Qi-Wei Jiang; Jie-Ying Wu; Jian-Ge Qiu; Wen-Ji Zhang; Xiao-Long Mei; Zhi Shi; Jin-Ming Di
Journal:  Oncotarget       Date:  2015-09-08

10.  ATR inhibition induces synthetic lethality and overcomes chemoresistance in TP53- or ATM-defective chronic lymphocytic leukemia cells.

Authors:  Marwan Kwok; Nicholas Davies; Angelo Agathanggelou; Edward Smith; Ceri Oldreive; Eva Petermann; Grant Stewart; Jeff Brown; Alan Lau; Guy Pratt; Helen Parry; Malcolm Taylor; Paul Moss; Peter Hillmen; Tatjana Stankovic
Journal:  Blood       Date:  2015-11-12       Impact factor: 22.113

View more
  3 in total

Review 1.  miRNAs in Lymphocytic Leukaemias-The miRror of Drug Resistance.

Authors:  Yordan Sbirkov; Bozhidar Vergov; Nikolay Mehterov; Victoria Sarafian
Journal:  Int J Mol Sci       Date:  2022-04-22       Impact factor: 6.208

2.  Homotypic targeting of immunomodulatory nanoparticles for enhanced peripheral and central immunity.

Authors:  Yubo Shen; Daoxia Guo; Xiaoyuan Ji; Yanfeng Zhou; Shuo Liu; Jing Huang; Haiyun Song
Journal:  Cell Prolif       Date:  2022-01-27       Impact factor: 6.831

3.  Elucidation of Focal Adhesion Kinase as a Modulator of Migration and Invasion and as a Potential Therapeutic Target in Chronic Lymphocytic Leukemia.

Authors:  Thomas A Burley; Andrew Hesketh; Giselda Bucca; Emma Kennedy; Eleni E Ladikou; Benjamin P Towler; Simon Mitchell; Colin P Smith; Christopher Fegan; Rosalynd Johnston; Andrea Pepper; Chris Pepper
Journal:  Cancers (Basel)       Date:  2022-03-22       Impact factor: 6.575

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.